Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Clinical trial NCT00628238 · UNKNOWN

Trial details

NCT number: NCT00628238
Sponsor: Chronic Lymphocytic Leukemia Research Consortium
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia CLL Untreated Front-line First-Line Initial Therapy

Start date: 2008-02-01
Primary completion: 2011-02-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.